Top Suppliers:I want be here

130804-35-2

130804-35-2 structure
130804-35-2 structure
  • Name: lecimibide
  • Chemical Name: 3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfanyl]pentyl]-1-heptylurea
  • CAS Number: 130804-35-2
  • Molecular Formula: C34H40F2N4OS
  • Molecular Weight: 590.76900
  • Catalog: Research Areas Metabolic Disease
  • Create Date: 2018-08-25 02:54:18
  • Modify Date: 2024-01-02 17:46:58
  • Lecimibide (DuP 128) is a potent and specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor for antihyperlipidemia research[1][2].

Name 3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenyl-1H-imidazol-2-yl)sulfanyl]pentyl]-1-heptylurea
Synonyms N'-(2,4-difluorophenyl)-N-[5-(4,5-diphenyl-1H-imidazol-2-ylthio)pentyl]-N-heptylurea
urea,n'-(2,4-difluorophenyl)-n-[5-[(4,5-diphenyl-1h-imidazol-2-yl)thio]pentyl]-n-heptyl
Lecimibide
Lecimibide (USAN)
Description Lecimibide (DuP 128) is a potent and specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor for antihyperlipidemia research[1][2].
Related Catalog
In Vitro Lecimibide (DuP 128)(10 μM, 24 h)可以抑制 HepG2 细胞 85% 的细胞酯化反应[1]。
In Vivo Lecimibide (DuP 128)(i.v., 2.2 mg/kg/day) 在饲养高脂肪和胆固醇的猪中,显著降低了总血浆甘油三酯和极低密度脂蛋白(VLDL)甘油三酯浓度,分别降低了 36% 和 31%。而对总胆固醇、VLDL 胆固醇、LDL 胆固醇、HDL 胆固醇或 LDL apoB 浓度没有显著影响[2]。
References

[1]. L J Wilcox, et al. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res. 2001 May;42(5):725-34.   

[2]. J R Burnett, et al. Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Biochim Biophys Acta. 1998 Jul 31;1393(1):63-79.  

Density 1.21g/cm3
Molecular Formula C34H40F2N4OS
Molecular Weight 590.76900
Exact Mass 590.28900
PSA 89.81000
LogP 9.80240
Index of Refraction 1.613

~58%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522

~%

130804-35-2 structure

130804-35-2

Literature: Higley; Wilde; Maduskuie; Johnson; Pennev; Billheimer; Robinson; Gillies; Wexler Journal of Medicinal Chemistry, 1994 , vol. 37, # 21 p. 3511 - 3522